Published in Blood Lymphat Cancer on April 19, 2012
Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity. Oncol Lett (2014) 0.84
New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol (2012) 0.75
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol (2017) 0.75
B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev Hematol (2016) 0.75
Prognostic value of miRNA-155 expression in B-cell Non-Hodgkin's lymphoma. Turk J Haematol (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med (1993) 17.71
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program (2009) 3.99
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 3.15
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol (2004) 2.98
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.80
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2007) 2.17
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol (2008) 2.15
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood (2004) 2.12
Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin (2010) 1.97
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med (1985) 1.97
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma (2008) 1.85
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 1.63
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (2008) 1.56
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer (2010) 1.38
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood (2003) 1.34
Diffuse large B-cell lymphoma. Arch Pathol Lab Med (2008) 1.27
Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am (2008) 1.21
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (2010) 1.17
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk (2011) 1.11
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood (2003) 1.10
A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk (2010) 1.09
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol (2010) 1.08
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer (2010) 1.05
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev (2008) 1.01
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant (2009) 1.00
The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res (2007) 0.94
Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology (2009) 0.91
Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med (1986) 0.87
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol (1990) 0.85
Novel agents for diffuse large B-cell lymphoma. Expert Opin Investig Drugs (2011) 0.83
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol (2000) 0.83
Diffuse large B-cell lymphoma in the young in Japan: a study by the Osaka Lymphoma Study Group. Am J Hematol (2007) 0.82
Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol (2009) 0.82
Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol (2000) 0.81
Maintenance therapy in lymphoma. Clin Lymphoma Myeloma (2007) 0.80
Apparent modulation of CD20 by rituximab: an alternative explanation. Blood (2004) 0.80
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leuk Lymphoma (2006) 0.79
Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. Saudi Med J (2010) 0.79
Improving our use and understanding of antibodies in B-cell lymphomas. Oncology (Williston Park) (2010) 0.79
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol (2000) 0.78
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 3.86
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park) (2015) 2.11
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood (2004) 2.04
Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma (2008) 1.85
Racial variation in colorectal polyp and tumor location. J Natl Med Assoc (2007) 1.60
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer (2010) 1.38
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res (2010) 1.29
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol (2009) 1.24
Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma (2013) 1.21
Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk (2011) 1.11
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol (2010) 1.08
Insurance status is related to diffuse large B-cell lymphoma survival. Cancer (2014) 1.04
A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol (2011) 1.04
Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res (2005) 1.04
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion (2011) 1.01
Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res (2009) 1.01
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol (2012) 0.96
Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. Cancer Inform (2007) 0.94
Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk (2010) 0.93
Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant (2007) 0.93
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood (2010) 0.93
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer (2013) 0.92
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol (2013) 0.91
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant (2012) 0.91
Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol (2015) 0.91
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer (2012) 0.89
Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) (2012) 0.87
Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform (2009) 0.87
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer (2013) 0.87
Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk (2011) 0.86
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk (2013) 0.85
Initial management strategies for follicular lymphoma. Int J Hematol Oncol (2012) 0.84
Using primary site as a predictor of survival in mantle cell lymphoma. Cancer (2013) 0.84
To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep (2015) 0.83
Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer (2013) 0.83
Patterns of social support among lymphoma patients considering stem cell transplantation. Soc Work Health Care (2011) 0.81
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer (2013) 0.80
ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer (2014) 0.80
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer (2014) 0.80
Clinical, molecular, and environmental risk factors for hodgkin lymphoma. Adv Hematol (2010) 0.80
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion (2010) 0.80
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma (2014) 0.79
Exploring risk factors for follicular lymphoma. Adv Hematol (2012) 0.79
New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther (2015) 0.78
A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk (2012) 0.78
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2014) 0.78
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant (2013) 0.78
Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Eur Oncol Haematol (2012) 0.78
Idiotype vaccine strategies for treatment of follicular lymphoma. Future Oncol (2011) 0.77
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion (2012) 0.77
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma (2014) 0.77
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol (2016) 0.77
Racial differences in chronic lymphocytic leukemia. Digging deeper. Cancer (2013) 0.76
ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park) (2013) 0.76
Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol (2012) 0.76
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.76
Peripheral T-cell lymphoma: what's the role for transplant? Oncology (Williston Park) (2013) 0.75
New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol (2012) 0.75
Considerations in the initial management of follicular lymphoma. Community Oncol (2012) 0.75
The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther (2013) 0.75
Routine use of maintenance therapy in follicular lymphoma: examine the rationale for maintenance use before uniformly adopting a strategy. Oncology (Williston Park) (2014) 0.75
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology (Williston Park) (2016) 0.75
Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. Expert Opin Biol Ther (2010) 0.75
Idiotype vaccine strategies for improving outcomes in follicular lymphoma. Expert Opin Biol Ther (2008) 0.75
Comparing the cost-effectiveness of the triple test score to traditional methods for evaluating palpable breast masses. Med Care (2003) 0.75
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Am J Clin Oncol (2015) 0.75
Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies. Oncology (Williston Park) (2013) 0.75
Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant (2007) 0.75
A Plethora of Novel Therapies--Which One to Choose? Oncology (Williston Park) (2015) 0.75
Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J (2005) 0.75
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Am J Clin Oncol (2016) 0.75